29 results about "Meticillin" patented technology

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

The invention relates to application of golden larch bark acetic acid in preparation of methicillin-resistant staphylococcus aureus (MRSA) biological membrane and bacterium holding inhibitor. A biological membrane formation inhibition experiment shows that the pseudolaric acid can remarkably inhibit formation of an MRSA biological membrane, a fluorescent quantitative PCR experiment shows that the pseudolaric acid remarkably reduces transcription of related genes of the MRSA biological membrane, and a persistent bacterium killing experiment shows that the pseudolaric acid enhances the killing capability of gentamicin on MRSA persistent bacteria. Lung epithelial cell adhesion tests find that the golden larch bark acetic acid significantly reduces the adhesion effect of the MRSA strain on epithelial cells. A test for constructing an MRSA infected greater wax moth model shows that the golden larch bark acetic acid has a system protection effect on the MRSA infected greater wax moth model.

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The invention discloses a manganese-based layered hydroxide modified by gold nanoparticles and a preparation method thereof, and relates to the technical field of drug synthesis, and the key points of the technical scheme are as follows: the layered morphology of Mn-LDH is observed on the manganese-based layered hydroxide in a transmission electron microscope, and spherical AuNPs dispersed on the surface and edge of a laminate have a uniform particle size and a uniform particle size. EDS energy spectrum analysis finds that gold, manganese, magnesium, aluminum and carbon elements exist, the hydrated particle size is 312 nm, and the dispersity is good. The material can initiate an excellent photo-thermal effect under the irradiation of 808nm near-infrared light to generate active oxygen and hydroxyl radicals to destroy bacterial cell walls and cell membranes, and the antibacterial effect can reach 99%. In addition, the material can stimulate a local active immune function, promote T cell infiltration and realize active immune sterilization. The nano material shows a remarkable anti-infection effect in an in-vitro antibacterial experiment and an in-vivo osteomyelitis animal model experiment, and a new insight is provided for treating osteomyelitis caused by methicillin-resistant staphylococcus aureus.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The application provides a fusariobutenolide derivative 4''-O-isopentenyl fusariobutenolide C, and a structural formula of the compound is provided.The 4''-O-isopentenyl fusariobutenolide C can significantly inhibit the growth of seven human routine pathogenic bacteria in antibacterial activity testing, and the MIC is 8.6-28.3 μg / mL, and the antibacterial effect on one strain of human drug-resistant pathogenic bacteria, methicillin-resistant Staphylococcus aureus, is significant, and the MIC is 16.8 μg / mL, and the 4''-O-isopentenyl fusariobutenolide C can be applied to preparation of antibacterial drug precursors, and lays a material foundation for next-step biological medicine development and application of antibacterial components.

The present application relates to the field of microbial technology, and discloses a strain XY-144, fermentation supernatant and application thereof.The Latin classification of the strain XY-144 is Fangia hongkongensis, the preservation unit is China General Microbiological Culture Collection Center, the preservation address is No. 1, Xibenchengli, Chaoyang District, Beijing, the preservation number is CGMCC No: 31090, and the preservation date is June 26, 2024.The fermentation supernatant prepared from the strain XY-144 can obviously inhibit the formation of methicillin-resistant Staphylococcus aureus biofilm and remove the methicillin-resistant Staphylococcus aureus biofilm, the fermentation supernatant has good thermal stability, no antibacterial activity and toxicity are found, so that the strain XY-144 and the fermentation supernatant thereof are safe and reliable in application in the food industry, which has great advantages in food application.

The application discloses an application of near-infrared controllable Fe, Zn doped tea polyphenol based carbon dot nanometer enzyme in fruit preservation, and belongs to the technical field of agricultural product preservation.The application takes tea polyphenol as a precursor, and prepares Fe, Zn doped carbon dots (Fe, Zn@GTP) nanometer enzyme with excellent antioxidant and antibacterial activity through a microwave assisted method.The Fe, Zn@GTP nanometer enzyme exhibits near-infrared light enhanced peroxidase, superoxide dismutase and catalase catalytic activity and photo-thermal performance.The Fe, Zn@GTP has antibacterial effects on escherichia coli, staphylococcus aureus, methicillin-resistant staphylococcus aureus, ampicillin-resistant escherichia coli and penicillium expansum, and the inhibition rate of the bacterial biofilm treated by the Fe, Zn@GTP is more than 90%.In the preservation experiment, the PVA / Fe, Zn@GTP film can effectively prolong the preservation period of fruits, significantly reduce the occurrence rate of fruit mold and browning, and the deterioration degree of quality indexes.

The application discloses a safe preservative-free sea dragon antibacterial peptide spray and a preparation method and application thereof. The spray contains sea dragon antibacterial peptide SsPle as an active ingredient and excipients. The amino acid sequence of the sea dragon antibacterial peptide SsPle is FFRSLWKGVKEGFRAGRSAYKA. The antibacterial peptide spray has the characteristics of safety, non-toxicity, non-inclusion of traditional preservatives, good stability, convenient use and the like. The antibacterial peptide has no acute oral toxicity, no mutagenicity and no chromosome damage risk, and has high biological safety. The spray is stable at 30 DEG C for 120 days, and still has a significant bacteriostatic effect on pseudomonas aeruginosa, methicillin-resistant staphylococcus aureus (MRSA) and the like. The preparation process is simple, the spray can be filled by using a quantitative sprayer, and the spray is convenient for clinical treatment, wound care and daily disinfection application. The application solves the problem of irritation of traditional antibacterial peptide sprays, is suitable for sensitive people, and has a broad market prospect.

The invention discloses an application of a bupleurum chinense extract in preparation of an antibacterial product. According to the invention, it is found for the first time that various extracts (including aqueous extracts, ethanol extracts and extraction parts of different polar solvents) of bupleurum chinense have relatively good bacteriostatic activity on streptococcus pneumoniae, methicillin-resistant staphylococcus epidermidis, micrococcus luteus and enterococcus faecium. The antibacterial spectrums and effects of different extracts are different, and the research lays a solid foundation for developing novel anti-drug-resistant bacteria drugs and natural-source antibacterial products.

The invention discloses two novel cytochalasin compounds with activity of inhibiting methicillin-resistant staphylococcus aureus (MRSA) and application of the cytochalasin compounds. The invention provides a compound shown as a formula (I) or a compound shown as a formula (II). The compound shown in the formula (I) is named as a compound Aizuchalasin A. The invention further discloses a preparation method of the compound. The compound shown in the formula (II) is named as a compound Aizuchlaasin B. The formula (I) is shown in the description. The compound A and the compound B of the Aizuchalasin have the activity of inhibiting methicillin-resistant staphylococcus aureus. The invention provides a lead compound for developing a new anti-MRSA medicine, and has great value for treating MRSA infection.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

The invention relates to the technical field of medical compounds, in particular to a self-sensitization anti-biofilm prodrug as well as a preparation method and application thereof. The self-sensitization anti-biofilm prodrug has a structure as shown in a formula I; wherein R1 is selected from a substituted or unsubstituted C6-C15 aryl group and a substituted or unsubstituted C6-C15 heteroaryl group, and a heteroatom in the C6-C15 heteroaryl group is selected from N; and R2 is selected from at least one of alkyl, keto and substituted or unsubstituted C6-C15 aryl. The self-sensitization anti-biofilm prodrug provided by the invention has good biofilm removal activity on methicillin-resistant staphylococcus aureus.

This invention belongs to the field of antibacterial nanomaterials, specifically relating to nanoparticles that inhibit methicillin-resistant Staphylococcus aureus (MRSA) resistance. The nanoparticles have a three-layer structure, consisting of a core layer composed of a copper nanoparticle and a copper oxide composite, a mesoporous graphite shell, and a bis(amino)PEG coating, from the inside out. The above method achieves physical encapsulation of copper nanoparticles by graphite using a one-step plasma arc method; and constructs a Cu / Cu₂O interface through precise oxygen-controlled thermal oxidation treatment, while simultaneously achieving effective protection and exposure of the active A layer by mesoporousizing the graphite; the use of bis(amino)PEG to form a polymer coating on the nanoparticles enhances bacterial uptake capacity and improves biocompatibility. The nanoparticles prepared by this invention can increase the utilization rate of drug-resistant bacteria by inhibiting bacterial biofilm structures and efflux pumps that cause bacterial infections, thereby improving the clearance capacity against drug-resistant bacterial infections and demonstrating great potential for application and clinical translation.

The application discloses carbon nanodots for resisting multi-drug resistant bacterial biofilm and a preparation method and application thereof. The carbon nanodots are prepared as follows: taking dopamine hydrochloride and diethylene triamine as raw materials, dissolving in deionized water, transferring the reaction solution to a reaction kettle, reacting at 80-200 DEG C for 1-24h, and subjecting the reaction product to dialysis and freeze-drying to obtain the carbon nanodots. The prepared carbon nanodots are used for resisting multi-drug resistant bacteria, methicillin-resistant Staphylococcus aureus (MRSA) biofilm. The results show that the carbon nanodots have excellent performance of inhibiting the formation of MRSA biofilm and eliminating mature MRSA biofilm. In addition, the carbon nanodots can be applied to the preservation of perishable foods such as strawberries. The preparation method is simple and easy to operate, has low cost and good reproducibility, provides entities and technical guidance for the prevention and treatment of biofilm related infections and food safety protection, and provides a basis for the preparation and application of multifunctional antimicrobial materials.

The invention discloses application of nerol as a quinolone antibiotic synergist in preparation of antibacterial infection drugs, and belongs to the technical field of antibiotic synergists. According to the invention, a natural monoterpene alcohol, namely nerol (Nerol), is adopted as a quinolone antibiotic synergist. The nerol can inhibit the efflux pump activity of methicillin-resistant staphylococcus aureus and recover the sensitivity of methicillin-resistant staphylococcus aureus to quinolone antibiotics, the nerol is combined with ciprofloxacin, norfloxacin or clinafloxacin for use, the nerol has a partial synergistic effect on methicillin-resistant staphylococcus aureus MRSA 95 strains, and the survival rate of mice infected with the methicillin-resistant staphylococcus aureus MRSA 95 strains can be remarkably improved. The invention provides a safe and effective new strategy for overcoming the drug resistance of quinolone antibiotics.

The application discloses a bacteriocin and application thereof in removing methicillin-resistant Staphylococcus aureus biofilm. A novel bacteriocin PFB252 is separated and identified, the bacteriocin is composed of 102 amino acids, and the relative molecular weight is 11267.34 Da. Research shows that the bacteriocin PFB252 has good thermal stability and pH stability and is acid-resistant, and the antibacterial activity still remains at 76.23%-95.20% after treatment of different proteases. The bacteriocin PFB252 can inhibit the growth of methicillin-resistant Staphylococcus aureus, reduce the biofilm formation amount of bacteria, the metabolic activity in the biofilm and the content of extracellular polysaccharide, and also can reduce the expression of biofilm-related genes, can effectively remove the methicillin-resistant Staphylococcus aureus biofilm, overcome the drug resistance of the methicillin-resistant Staphylococcus aureus, and has important significance for preventing and treating the methicillin-resistant Staphylococcus aureus in clinic.

The present application relates to a SERS biosensor, which is a hairpin probe DNA modified on the surface of small-particle-size AuNPs, and a protective DNA and a Raman dye modified on the surface of large-particle-size AuNPs; an aptamer, trigger chain 1 and 2 are combined into a triple-stranded structure; then the target bacteria and exonuclease III are mixed and added for enzymatic reaction, finally a SERS hot spot is generated and a very strong SERS signal is generated, the supernatant is taken for SERS detection, and the rapid detection of the target bacteria-methicillin-resistant Staphylococcus aureus can be realized. The present application combines the traditional colorimetric analysis method and multi-stage nucleic acid amplification together, can quickly convert the trace target signal into Raman signal output through multi-stage signal amplification, and realizes the specific early rapid detection of the target bacteria.

The invention provides a berberine derivative as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the derivative, an acyl acetophenone substituent group is introduced to the 9 site of berberine, and a series of 9-site substituted berberine compounds are specifically designed and synthesized. In-vitro antimicrobial activity detection shows that the compounds have excellent inhibitory activity on gram-positive bacteria (staphylococcus aureus and methicillin-resistant staphylococcus aureus) and gram-negative bacteria (escherichia coli, shigella flexneri, shigella dysenteriae and vibrio parahaemolyticus), can be used for preparing antibacterial drugs, do not have obvious drug resistance, and can be used for preparing antibacterial drugs. And a more efficient and safer candidate drug can be provided for the treatment of clinical diarrhea related diseases.

The invention discloses application of a traditional Chinese medicine flastem milkvetch seed (astragalus complanatus seed) extract in preparation of antibacterial products. The invention finds that the flastem milkvetch seed extract has better inhibitory activity on staphylococcus epidermidis, methicillin-resistant staphylococcus epidermidis, escherichia coli, staphylococcus aureus and pseudomonas aeruginosa for the first time, and the extract can be developed into novel antibacterial products (daily necessities, cosmetics, word size eliminating products and medicines). The invention provides a new plant resource for research and development of a novel natural bacteriostatic agent.

The application discloses a heavy Zanthoxylum bungeanum essential oil component with antibacterial activity and a preparation method thereof. The Zanthoxylum bungeanum essential oil is deeply researched, and the Zanthoxylum bungeanum essential oil is separated into a light Zanthoxylum bungeanum essential oil component and the heavy Zanthoxylum bungeanum essential oil component through a molecular distillation instrument. The antibacterial and antifungal experimental results show that the heavy Zanthoxylum bungeanum essential oil component obtained through distillation refining has better bactericidal activity on Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, Staphylococcus aureus and corynebacterium striatum compared with the Zanthoxylum bungeanum essential oil and the light Zanthoxylum bungeanum essential oil component, and has better bactericidal activity on Candida tropicalis, Candida krusei, Candida glabrata and white Candida, and a good technical effect is achieved.

This invention relates to a novel methicillin-resistant Staphylococcus aureus (MRSA) bacteriophage and its applications. The invention provides a methicillin-resistant MRSA bacteriophage SP01, which is identified as a new species. This phage possesses highly efficient lytic ability against MRSA and has a broad host spectrum, showing sensitivity to multiple clinical isolates. Furthermore, phage SP01 exhibits excellent environmental stability, maintaining good activity within a temperature range of 4–40°C and a pH range of 7–11. In summary, this invention allows for the preparation of drugs, disinfectants, and bactericides for treating MRSA infections using phage SP01, addressing the problem of conventional antibiotic ineffectiveness and demonstrating broad application prospects.

The invention provides a medical application of resortanol in preparation of a staphylococcus aureus inhibitor, belongs to the technical field of biological medicines, and provides a novel medical application of resortanol, which can significantly inhibit growth of methicillin-resistant staphylococcus aureus and formation of a biofilm, and can inhibit the growth of methicillin-resistant staphylococcus aureus. The survival rate of methicillin-resistant staphylococcus aureus infection greater wax moth larvae can be obviously improved; the compound can be used for preparing a staphylococcus aureus inhibitor, a new candidate drug is provided for clinical treatment of multi-drug-resistant staphylococcus aureus infection, and the resorpterol and appropriate pharmaceutic adjuvants can be prepared into an injection for preparing drugs for systemic infection caused by methicillin-resistant staphylococcus aureus.

The present application aims to provide a eucheuma extract, a preparation method and application thereof, and the preparation method comprises the following steps: cutting eucheuma whole grass, using distilled water and 75% ethanol as extraction solvents respectively, hot reflux extraction twice, combining the filtrates, concentrating under reduced pressure, and evaporating the solvent to dryness to prepare a dry paste, and obtaining eucheuma water extract and eucheuma alcohol extract respectively. The eucheuma water extract and alcohol extract provided by the present application have significant inhibitory effects on staphylococcus aureus, escherichia coli, staphylococcus epidermidis, methicillin-resistant staphylococcus epidermidis, sarcina, bacillus, pseudomonas aeruginosa, enterococcus faecium, micrococcus luteus, acinetobacter baumannii, streptococcus pneumoniae and klebsiella pneumoniae, and have great development potential in the future research on bacteriostatic drugs, bacteriostatic cleaning products and other bacteriostatic products.

The invention relates to the field of antibacterial agents, in particular to marine bioalkali biquaternary ammonium salt as well as a pharmaceutical composition and antibacterial application thereof. The novel biquaternary ammonium salt is constructed based on marine bioalkali eudistomin N through a pharmacophore splicing strategy, has a structural formula as shown in a formula I, has broad-spectrum antibacterial activity, is used for inhibiting growth of bacteria such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and salmonella enteritidis, and can be used for inhibiting growth of bacteria such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and salmonella enteritidis. The compound is particularly used for inhibiting escherichia coli ATCC 8739 or resisting klebsiella pneumoniae ATCC 10031.

The application discloses a lactobacillus plantarum resisting multiple drug-resistant bacteria and application thereof, and a lactobacillus plantarum 6-14 is separated from collected wild bird excrement, the bacterium has obvious inhibiting effect on multiple drug-resistant bacteria and non-drug-resistant bacteria, including inhibiting methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus faecalis, penicillin-resistant streptococcus pneumoniae, staphylococcus aureus, escherichia coli, salmonella enteritidis and salmonella typhimurium, and the application lays a foundation for developing good antibacterial probiotic preparations.

The invention provides broad-spectrum salt ion tolerance staphylococcus aureus bacteriophage lyase and application, and belongs to the technical field of microorganisms. The lyase comprises an amino acid sequence shown as SEQ ID NO.2, or the lyase has at least 95% of homology with the amino acid sequence shown as SEQ ID NO.2 and has the same function as the amino acid sequence shown as SEQ ID NO.2. The staphylococcus aureus bacteriophage lyase provided by the invention has relatively good water solubility, salt ion and pH tolerance and temperature stability, is relatively wide in host spectrum, and can inhibit growth of methicillin-resistant and oxacillin-resistant staphylococcus aureus in chicken, clear biological membranes of the methicillin-resistant and oxacillin-resistant staphylococcus aureus, inhibit growth of the methicillin-resistant and oxacillin-resistant staphylococcus aureus, inhibit growth of the methicillin-resistant and oxacillin-resistant staphylococcus aureus and inhibit growth of the methicillin- no cytotoxicity exists.